ORIC PHARMACEUTICALS INC
NASDAQ: ORIC (Oric Pharmaceuticals, Inc.)
Last update: 52 minutes ago11.39
0.41 (3.73%)
| Previous Close | 10.98 |
| Open | 10.91 |
| Volume | 1,266,442 |
| Avg. Volume (3M) | 1,368,470 |
| Market Cap | 1,109,263,872 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 3.97% |
| Current Ratio (MRQ) | 12.00 |
| Operating Cash Flow (TTM) | -115.01 M |
| Levered Free Cash Flow (TTM) | -68.48 M |
| Return on Assets (TTM) | -30.87% |
| Return on Equity (TTM) | -48.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Oric Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.93% |
| % Held by Institutions | 102.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nextech Invest, Ltd. | 30 Sep 2025 | 7,162,637 |
| Nextech Invest Ltd. | 31 Dec 2024 | 5,285,714 |
| Column Group Llc | 30 Sep 2025 | 3,540,777 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Evercore ISI Group, 119.49%) | Buy |
| Median | 19.50 (71.20%) | |
| Low | 15.00 (Oppenheimer, 31.69%) | Buy |
| Average | 19.67 (72.70%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 12.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 20 Nov 2025 | 25.00 (119.49%) | Buy | 11.48 |
| JP Morgan | 18 Nov 2025 | 20.00 (75.59%) | Buy | 11.90 |
| Citigroup | 17 Nov 2025 | 16.00 (40.47%) | Buy | 12.06 |
| HC Wainwright & Co. | 14 Nov 2025 | 23.00 (101.93%) | Buy | 12.25 |
| Oppenheimer | 14 Nov 2025 | 15.00 (31.69%) | Buy | 12.25 |
| Wells Fargo | 14 Nov 2025 | 19.00 (66.81%) | Buy | 12.25 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |